Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.
Fiche publication
Date publication
avril 2020
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Mme TRUNTZER Caroline, Dr FUMET Jean-David
Tous les auteurs :
Fumet JD, Truntzer C, Yarchoan M, Ghiringhelli F
Lien Pubmed
Résumé
Treatment with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer types, but only in a subset of patients. The use of predictive biomarkers for response to PD-1/PD-L1 inhibitors is critical for patient selection. Expression of PD-L1 has demonstrated utility in patient selection. Tumour mutational burden (TMB) is an emerging biomarker for response to PD-1/PD-L1 inhibitors. The evaluation of this biomarker is based on the hypothesis that a high number of mutations in somatic exonic regions will lead to an increase in neoantigen production, which could then be recognised by CD8 T cells, resulting in improved immune responses. In this review, we will discuss rationale and implementation of TMB usage in patients, development of different methods to assess it, current limitations and technical issues to use this biomarker as a diagnostic test and propose future perspectives beyond TMB.
Mots clés
Biomarker, Immunotherapy, Tumour mutational burden
Référence
Eur. J. Cancer. 2020 Apr 9;131:40-50